QMed, Inc. Receives 2-Year Extension of Medicare Coordinated Care Demonstration Proj... (coordination we are very pleased with ou...)

QMed, Inc. Receives 2-Year Extension of Medicare Coordinated Care Demonstration Project by CMS

Date:4/7/2008

coordination, we are very pleased with our outcomes to date and are honored to be one of the three remaining sites selected by CMS. As care coordination of today's Medicare population is so vital to the future of our industry, we look forward to working with CMS in the MCCD and possible future demonstration projects in the years to come."

About the Medicare Coordinated Care Demonstration

MCCD is one of the first studies of chronic care coordination under fee- for-service Medicare. It was designed to test whether care coordination services can lower costs, increase patient satisfaction and improve quality of care for Medicare Beneficiaries with chronic illnesses.

The coordinated care demonstration was authorized by Section 4016 of the Balanced Budget Act of 1997 (BBA). The BBA requires that the projects target chronically ill Medicare fee-for-service beneficiaries that are eligible for both Medicare Parts A and B.

About QMed, Inc.

QMed has developed evidence-based clinical information management systems for use by health plan customers. The QMed systems incorporate Disease Management services to patients and decision support to physicians. The Company's subsidiaries have specialized in serving high-risk populations of Medicare beneficiaries.

Except for historical information contained herein, matters discussed in this news release are forward-looking statements that involve risks and uncertainties. They include but are not limited to those relating to the timely implementation of programs, the impact of business and operational conditions, competitive product introductions, acceptance and pricing, and those risks detailed in the Company's filings with the Securities and Exchange Commission (SEC). Actual results may differ materially from any forward- looking statements due to these risks and uncertainties.

Contact: William Schmitt, QMed, Inc. - 732-544-5544 x1112

0

GOOD

Page: 1 2
Related medicine technology :

1. Thermo Fisher Scientific Receives FDA Clearance for MRSA Test Medium
2. Vical Receives NIH Grant for an Immunotherapeutic Herpes DNA Vaccine; Herpes Experts at University of Washington and University of Texas to Conduct Preclinical Development
3. DermaGen AB Receives Over 1 Million Euros From a New Share Issue
4. PLC Systems Receives FDA Approval to Commence Pivotal Study Of RenalGuard(TM) In the U.S.
5. Diamyd(R) Diabetes Vaccine Receives Approval to Start Phase III Trials in Europe
6. Microbicide Developer Receives License for Novel HIV Microbicide Candidate From Merck & Co., Inc.
7. Florastor(R) Receives ConsumerLab.com Certification
8. DuraHeart(TM) LVAS Receives Conditional Approval for US Pivotal Trial
9. Vermillion Receives Award From the Society of Gynecologic Oncologists
10. Arbios Receives Conditional Approval from the FDA to Initiate Pivotal Clinical Trial for SEPET(TM)
11. ActivBiotics Receives Orphan Drug Designation from the European Medicines Agency for Superoxide Dismutase Mimetic, M40403, in Oral Mucositis Indication

Post Your Comments:

QMed, Inc. Receives 2-Year Extension of Medicare Coordinated Care Demonstration Proj...(coordination we are very pleased with ou...),Health